临床与病理杂志2018，Vol.38Issue(3)：498-503,6.DOI:10.3978/j.issn.2095-6959.2018.03.006
139例肺癌小活检标本EGFR,ALK,ROS1基因状态分析
Analysis of the mutation state of EGFR, ALK and ROS1 genes in 139 biopsy specimens of lung cancer
刘春样 1孙怡 1高丽丽 1王耀辉 1章宜芬 1王剑蓉1
作者信息
- 1. 南京中医药大学附属医院病理科,南京 210029
- 折叠
摘要
Abstract
Objective: To evaluate EGFR, ALK and ROS1 gene mutation rate in biopsy specimens of primary lung cancer. Methods: Between January 2014 and January 2017, 139 biopsy specimens of primary lung cancer were included in this study and the clinicopathological data, and EGFR, ALK and ROS1 mutation status were reviewed. Results: The EGFR-TKIs sensitive mutations were detected in 38.85％ (54/139) patients, and the mutation rate of adenocarcinoma was 49.52％ (52/105), mutation rate of squamous cell carcinoma was 4.17％ (1/24), and mutation rate of NSCLC-NOS was 12.50％ (1/8). The mutation rate of adenocarcinoma was significantly higher than other types of lung cancer (P=0.0001). 30.39％ (31/102) male and 62.16％ (23/37) female patients carried EGFR mutation respectively. The mutation rate of female patients was significantly higher than that of male patients (P=0.0014). The mutation rates of non-smokers and smokers were 53.13％ (34/64) and 26.67％ (20/75) respectively, and the mutation rate of non-smokers was significantly higher than that of smokers (P=0.0017). Mutation rates in patients with clinical stage I, stage II and stage III were 33.33％ (1/3), 0.00％ (0/3), and 8.70％ (2/23) separately, and the mutation rate of stage IV patients was 47.19％ (42/89), and the mutation rate in patients with stage unknown was 42.86％ (9/21). The mutation rate of stage IV patients was significantly higher than that of patients with stage I, II and III (P=0.0038). The types of EGFR mutation included: E19-del accounting for 44.44％ (24/54), L858R accounting for 51.85％ (28/54), L861Q and S768I accounting for 1.85％ (1/54) separately. ALK fusion gene positive rate was 3.28％ (2/61), all of which were non-smokers with adenocarcinoma. ROS1 fusion gene positive rate was 1.72％ (1/58), who was a nonsmoking man with squamous cell carcinoma. Conclusion: EGFR-TKIs sensitive mutations are commonly seen in females, non-smokers and adenocarcinoma patients. ALK fusion is found in non-smokers with adenocarcinoma. ROS1 fusion can be detected in patients with squamous cell carcinoma.关键词
肺癌/活检/EGFR基因/ALK基因/ROS1基因Key words
lung cancer/biopsy/EGFR gene/ALK gene/ROS1 gene引用本文复制引用
刘春样,孙怡,高丽丽,王耀辉,章宜芬,王剑蓉..139例肺癌小活检标本EGFR,ALK,ROS1基因状态分析[J].临床与病理杂志,2018,38(3):498-503,6.
